InflaRx to present late-breaking preclinical izicopan data at ASN Kidney Week 2026

• InflaRx announced it will present late-breaking preclinical data on oral C5aR1 antagonist izicopan at Kidney Week 2026.
• The poster is scheduled for Oct. 22, 2026, positioning the program ahead of planned development in ANCA-associated vasculitis.
• Preclinical findings indicate therapeutic potential in kidney disease models, supporting broader renal expansion beyond earlier human studies.
• Prior clinical work cited showed a clean safety profile, supporting continued investment in the asset’s development pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020730PRIMZONEFULLFEED9838629) on October 02, 2026, and is solely responsible for the information contained therein.